Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3425-3435

  Rider, Lisa G ^a   Lachenbruch, Peter A ^b   Monroe, Jason B ^a   Ravelli, Angelo ^c   Cabalar, Imelda ^d   Feldman, Brian M ^e   Villalba, Maria L ^f   Myones, Barry L ^g   Pachman, Lauren M ^h   Rennebohm, Robert M ⁱ   Reed, Ann M ^j   Miller, Frederick W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ADOLESCENT; ADULT; ARTICLE; CALCINOSIS; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIP CONTRACTURE; HUMAN; JUVENILE; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDITIS; POLYMYOSITIS; PRIORITY JOURNAL; SCAR FORMATION; SCHOOL CHILD; SCORING SYSTEM;

ADOLESCENT; ADULT; CALCINOSIS; CHILD; CICATRIX; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCULAR ATROPHY; MYOSITIS; POLYMYOSITIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 70350546006     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24904     Document Type: Article

References (36)

1. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Longterm survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004;83:35-42. (Pubitemid 38124854)
2. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-549 (Pubitemid 30394944)
3. Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008;84:68-74. (Pubitemid 351287725)
4. Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 2008;26(5 Suppl 51):S109-14.
5. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1262-1273 (Pubitemid 33100092)
6. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-369 (Pubitemid 26085211)
7. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43:49-54.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-347
9. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-617 (Pubitemid 36301957)
10. Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989;16:1225-1228 (Pubitemid 19260112)
11. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392-399 (Pubitemid 28128762)
12. Adams EM, Pucino F, Yarboro C, Hicks JE, Thornton B, Mc- Garvey C, et al. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 1999;26:352-360 (Pubitemid 29066739)
13. Cabalar IP, Villalba L, Sherman J, Yarboro C, Cintas H, Koziol D, et al. A pilot study of the effect of methimazole, a drug that down-regulates MHC class I, on dermatomyositis and polymyositis [abstract]. Arthritis Rheum 2001;44 Suppl 9:S353.
14. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Arthritis Rheum 1997;40:1976-1983
15. Harris-Love M, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009;48:134-139
16. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. J Rheumatol 2001;28:1106-1111 (Pubitemid 32422597)
17. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Workshop report: defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-617 (Pubitemid 36301957)
18. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995;2:1-9.
19. Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, Miller FW, et al. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion- recovery MR imaging. Radiology 1998;209:191-196
20. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008;87:70-86.
21. Hardin JW, Hilbe JM. Generalized estimating equations. Boca Raton (FL): Chapman & Hall/CRC; 2003.
22. Bendel RB, Afifi AA. Comparison of stopping rules in forward stepwise regression. J Am Stat Assoc 1977;72:46-53.
23. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-662
24. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58:556-562
25. Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR, et al. Assessment of damage in juvenileonset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003;49:501-507 (Pubitemid 36988304)
26. Alarcon GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 2004;43:202-205
27. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:276-279 (Pubitemid 36305614)
28. Al-Mayouf SM, Al Sonbul A. Influence of gender and age of onset on the outcome in children with systemic lupus erythematosus. Clin Rheumatol 2008;27:1159-1162
29. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005;52:4003-4010
30. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002;46:436-444 (Pubitemid 34136581)
31. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-1480
32. Dayal NA, Gordon C, Tucker L, Isenberg DA. The SLICC damage index: past, present and future. Lupus 2002;11:261-265 (Pubitemid 34506733)
33. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and longterm outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008;152:550-556
34. Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2989-2996 (Pubitemid 44497780)
35. Bernatsky S, Clarke A, Abrahamowicz M, Neville C, Karp I, Pineau CA. A comparison of prospective and retrospective evaluations of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for systemic lupus erythematosus. J Rheumatol 2005;32:820-823 (Pubitemid 40676489)
36. Cassano G, Roverano S, Paira S, Bellomio V, Lucero E, Berman A, et al. Accrual of organ damage over time in Argentine patients with systemic lupus erythematosus: a multi-centre study. Clin Rheumatol 2007;26:2017-2022 (Pubitemid 350120337)